It’s been a while since I have blogged on Ion Torrent data.  There are several reasons for this.

First and foremost is that my head has been buried in The Archon Genomics XPrize Validation Protocol in which we were contracted to execute staring at the end of last year.  The AGXP is an ambitious, incentivized prize competition that will award $10 million to the first team to rapidly, accurately, and economically sequence 100 whole human genomes to a level of accuracy never before achieved.  The VP provides an opportunity to test and score current WGS technologies, assist the scientific community in establishing the reference genome(s) for this Competition and the means for analyzing the results of the Competition.

Second, it was with great anticipation and excitement that we received our Certificate of Compliance recently from the US Dept. of Health and Human Services Centers for Medicare and Medicaid Services. This means we have been deemed a CLIA lab and can begin to offer our Clinical Exome test under CLIA guidelines.  No small feat.

But, here I am, again, knocking the dust off the blogging boots, and wading into another data set Ion Torrent has publically released. 

The Life Technologie's Ion Torrnet  Bus stoped at EdgeBio in Gaithersburg, Maryland. Here they talked with President and CEO Dean Gaalaas about how EdgeBio has successfully been using the Ion PGM Sequencer in their service lab for over a year now. The Ion Torrent PGM Sequencer's speed has enabled EdgeBio to dramatically increase sequencing turnaround times, from weeks to days.

We would like to thank Genomeweb for their recent articles regarding the announcement of our CLIA status. If you missed the articles from Genomeweb you can view them here:  Clinical Exome Sequencing and EdgeBio Recieves CLIA Certification

Request a Quote for your Exome Sequencing Project

A few weeks ago we received our CLIA certification for next generation sequencing and will offer clinical exome sequencing for large labs and hospitals that can do their own in-house analysis. We will supply aligned sequencing data and leave the interpretation to the customers themselves.

It was with great anticipation and excitement that we received our Certificate of Compliance yesterday from the US Dept. of Health and Human Services Centers for Medicare and Medicaid Services. This, paired with our compliance letter from the State of Maryland, means we have been deemed a CLIA lab and can begin to offer our Clinical Exome test under CLIA guidelines. It’s been quite a journey to get here and everyone is quite excited to receive this designation and achieve this milestone.

Contributed by Dr. Samuel Levy : Director of Genomic Sciences - Scripps Translational Science Institute and Scripps Genomic Medicine, Professor of Molecular and Experimental Medicine - The Scripps Research Institute

AmpliSeq Cancer Panel applied to a tumor and blood sample pair for the detection of common somatic mutations

We have a clinical research protocol that aims to provide tumor mutation data to oncologists as part of a patient’s cancer care within the Scripps network and we were trying to figure out ways of providing these data in a time sensitive manner to patients and their physicians.  Whilst both exome and whole genome sequencing are good options, we wanted to maximize the use of any large amount of data we generate in an oncologist’s care approach. Consequently we decided that these options were data overkill for what a treating oncologist typically employs.